我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
2
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2014
进行中（未招募）
1
50.0%
已完成
暂无批准数据
- Aptahem AB received Notice of Allowance in China for patent application covering nucleic acid molecules with anti-inflammatory, anti-coagulant, and organ-protective properties. - The granted patent will provide intellectual property protection until 2038 for the company's RNA-based pharmaceutical technology platform. - CEO Mikael Lindstam emphasized that Chinese patent protection strengthens Aptahem's global position and attractiveness to potential partners in one of the world's largest pharmaceutical markets. - The company's lead candidate Apta-1 is currently in early clinical phase development for treating sepsis and related critical conditions.
